ChemicalBook
Chinese English Japanese Germany Korea

디디아이

디디아이
디디아이 구조식 이미지
카스 번호:
69655-05-6
한글명:
디디아이
동의어(한글):
디다노신;디디아이;디디아이(DDI)
상품명:
Dideoxyinosine
동의어(영문):
DDI;ddino;VIDEX;DDLNO;bmy40900;Didansine;nsc612049;2',3'-ddI;DIDANOSINE;2.3-Dideoxy
CBNumber:
CB0680765
분자식:
C10H12N4O3
포뮬러 무게:
236.23
MOL 파일:
69655-05-6.mol

디디아이 속성

녹는점
193-195 °C
끓는 점
193-195 C
알파
D25 -26.3° (c = 10 in water)
밀도
1.2917 (rough estimate)
굴절률
-28 ° (C=0.34, H2O)
저장 조건
2-8°C
용해도
Soluble in DMSO or methanol
물리적 상태
Powder
산도 계수 (pKa)
9.12(at 25℃)
색상
White to Off-white
수용성
1-5 g/100 mL at 21 ºC
Merck
14,3098
BRN
3619529
안정성
Stable. Combustible. Incompatible with strong oxidizing agents.
CAS 데이터베이스
69655-05-6(CAS DataBase Reference)
EPA
Inosine, 2',3'-dideoxy-(69655-05-6)
안전
  • 위험 및 안전 성명
  • 위험 및 사전주의 사항 (GHS)
위험품 표기 C
위험 카페고리 넘버 34-36/37
안전지침서 26-27-36/37/39-45-24/25
WGK 독일 2
RTECS 번호 NM7460700
HS 번호 29335990
유해 물질 데이터 69655-05-6(Hazardous Substances Data)
그림문자(GHS):
신호 어: Warning
유해·위험 문구:
암호 유해·위험 문구 위험 등급 범주 신호 어 그림 문자 P- 코드
H341 유전적인 결함을 일으킬 것으로 의심됨 (노출되어도 생식세포 유전독성을 일으키지 않는다는 결정적인 증거가 있는 노출경로가 있다면 노출경로 기재) 생식세포 변이원성 물질 구분 2 경고 P201,P202, P281, P308+P313, P405,P501
H373 장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킬 수 있음 특정 표적장기 독성 - 반복 노출 구분 2 경고 P260, P314, P501
예방조치문구:
P201 사용 전 취급 설명서를 확보하시오.
P202 모든 안전 조치 문구를 읽고 이해하기 전에는 취급하지 마시오.
P260 분진·흄·가스·미스트·증기·...·스프레이를 흡입하지 마시오.
P280 보호장갑/보호의/보안경/안면보호구를 착용하시오.
P308+P313 노출 또는 접촉이 우려되면 의학적인 조치· 조언를 구하시오.
P405 밀봉하여 저장하시오.
P501 ...에 내용물 / 용기를 폐기 하시오.

디디아이 MSDS


Dideoxyinosine

디디아이 C화학적 특성, 용도, 생산

개요

Didanosine is an orally active purine dideoxynucleoside analog indicated for adult and pediatric patients with advanced HIV infection who are either intolerant or significantly deteriorated on zidovudine. It appears to increase CD4 cell counts and decrease p24 antigen levels.Major adverse effects are pancreatitis, peripheral neuropathy and diarrhea.Unlike zidovudine, didanosine exhibits insignificant bone marrow suppression.

화학적 성질

White Powder

Originator

National Cancer Institute(NIH) (U.S.A.)

용도

Used as an antiviral

용도

Antiviral;Transrcriptase inverse inhibitor

정의

ChEBI: A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen.

Indications

Didanosine (ddI, Videx) is an adenosine analogue with activity against HIV-1, HIV-2, and HTLV-I. It is approved as part of a multidrug regimen for the therapy of HIV infection and is also used as postexposure HIV prophylaxis

상표명

Videx (Bristol-Myers Squibb).

Antimicrobial activity

Didanosine is active against HIV-1, HIV-2 and HTLV-1.

원료

Codon changes at positions 65 or 74 in HIV reverse transcriptase are associated with reduced susceptibility.

일반 설명

Fluffy white solid or powder. Condenses at 347°F and darkens at approximately 572°F. Odorless.

일반 설명

Didanosine (Videx, ddI) is 2',3'-dideoxyinosine (ddI), a synthetic purine nucleoside analog that is bioactivatedto 2',3'-dideoxy-ATP (ddATP) by host cellularenzymes.The metabolite, ddATP, accumulates intracellularly,where it inhibits RT and is incorporated intoviral DNA to cause chain termination in HIVinfectedcells. The potency of didanosine is 10-to 100-foldless than that of AZT with respect to antiviral activity andcytotoxicity, but the drug causes less myelosuppressionthan AZT causes.
Didanosine is recommended for the treatment of patientswith advanced HIV infection who have received prolongedtreatment with AZT but have become intolerant to, or experiencedimmunosuppression from, the drug. AZT and ddIact synergistically to inhibit HIV replication in vitro, andddI is effective against some AZT-resistant strains of HIV.Painful peripheral neuropathy (tingling, numbness, and painin the hands and feet) and pancreatitis (nausea, abdominalpain, elevated amylase) are the major dose-limiting toxicitiesof didanosine. Didanosine is given orally in the form ofbuffered chewable tablets or as a solution prepared from thepowder. Both oral dosage forms are buffered to preventacidic decomposition of ddI to hypoxanthine in the stomach.

공기와 물의 반응

Water soluble.

건강위험

SYMPTOMS: Symptoms of exposure to a related compound include cutaneous eruptions, fever, mouth sores, thrombocytopenia, neutropenia, reversible peripheral neuropathy, gastrointestinal distress, headache, nausea and vomiting.

화재위험

Flash point data for Dideoxyinosine are not available; however, Dideoxyinosine is probably combustible.

Pharmaceutical Applications

An analog of deoxyadenosine, formulated for oral administration.

Pharmacokinetics

Oral absorption: c. 40%
Cmax 400 mg once daily: 0.93 mg/L
Plasma half-life: c. 1.4 h
Volume of distribution: c. 1 L/kg
Plasma protein binding: <5%
Absorption
Bioavailability is reduced by about half when taken with food and the drug should be given at least 30 min before a meal. The peak plasma concentration achieved by enteric-coated tablets is less than half that of buffered tablets.
Distribution
Central nervous system (CNS) penetration is relatively poor. Median concentrations in semen (455 ng/mL; range < 50–2190 ng/mL) are greater than those in blood (<50 ng/mL; range <50–860 ng/mL). It is secreted in breast milk.
Metabolism
Based upon animal studies it is presumed that metabolism occurs by the pathways responsible for the elimination of endogenous purines by xanthine oxidase. Metabolism may be altered in patients with severe hepatic impairment; however, no specific dose adjustment is recommended.
Excretion
Renal clearance by glomerular filtration and active tubular secretion accounts for 50% of total body clearance. Urinary recovery accounts for about 20% of the oral dose in adults. The half-life increases three-fold in patients requiring dialysis. Patients with a creatinine clearance <60 mL/min may be at greater risk of toxicity.

Clinical Use

Treatment of HIV infection (in combination with other antiretroviral drugs)

Clinical Use

The most common adverse effect produced by didanosine is diarrhea.Abdominal pain, nausea, vomiting, anorexia, and dose-related peripheral neuropathy may occur. Pancreatitis occurs rarely, as do hyperuricemia, bone marrow suppression, retinal depigmentation, and optical neuritis. Resistance to didanosine appears to result from mutations different from those responsible for zidovudine resistance.

부작용

Most serious are pancreatitis (fatal and non-fatal), lactic acidosis and severe hepatomegaly with steatosis (fatal and nonfatal), retinopathy, optic neuritis and dose-related peripheral neuropathy. Patients with low body weight may require dose modification. A strong association with non-cirrhotic portal hypertension has been described.
The combination with stavudine should be avoided in pregnant women as fatal cases of lactic acidosis have been reported. Caution should also be exercised in patients with known risk factors for liver disease. Therapy should be stopped in patients who develop clinical or laboratory evidence of lactic acidosis or hepatotoxicity. Monitoring lactate levels prospectively is not recommended as mild hyperlactatemia occurs in asymptomatic patients and has a poor positive predictive value for the development of lactic acidosis.
Caution should be exercised in co-administering other drugs with known neurotoxicity and in patients with a history of neuropathy. Treatment should stop if symptoms and signs of neuropathy are observed, but the condition is usually reversible and patients with resolved neuropathy may be retreated at a reduced dosage. Retinal depigmentation has been observed in children and twice-yearly dilated retinal examination is recommended.

주의 사항

Buffering agents that are compounded with didanosineto counteract its degradation by gastric acid mayinterfere with the absorption of other drugs that requireacidity (e.g., indinavir, delavirdine, ketoconazole, fluoroquinolones,tetracyclines, dapsone). An enteric-coatedformulation (Videx EC) that dissolves in the basic pH ofthe small intestine is not susceptible to these interactions.Ganciclovir and valganciclovir can increase bloodlevels of didanosine.The use of zalcitabine with didanosineis not recommended because that combination carriesan additive risk of peripheral neuropathy.The combinationof didanosine with stavudine increases the riskof pancreatitis, hepatotoxicity, and peripheral neuropa-thy. Stavudine should not be given with didanosine topregnant women because of the increased risk of metabolicacidosis.

디디아이 준비 용품 및 원자재

원자재

준비 용품


디디아이 공급 업체

글로벌( 231)공급 업체
공급자 전화 팩스 이메일 국가 제품 수 이점
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 Abel@chembj.com CHINA 3194 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817
info@dakenchem.com CHINA 21726 58
Henan Tianfu Chemical Co.,Ltd.
0371-55170693
0371-55170693 info@tianfuchem.com CHINA 20672 55
Mainchem Co., Ltd.
+86-0592-6210733
+86-0592-6210733 sales@mainchem.com CHINA 32447 55
career henan chemical co
+86-371-86658258
sales@coreychem.com CHINA 30004 58
Nanjing Baifuli Technology Co., Ltd.
+86-15335185688
sales@unisyn.cn CHINA 332 58
Chongqing Chemdad Co., Ltd
+86-13650506873
sales@chemdad.com CHINA 30864 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63729 58
Shanghai Boyle Chemical Co., Ltd.
86-21-57758967 sales@boylechem.com China 2926 55
J & K SCIENTIFIC LTD. 400-666-7788 +86-10-82848833
86-10-82849933 jkinfo@jkchemical.com;market6@jkchemical.com China 96815 76

디디아이 관련 검색:

Copyright 2019 © ChemicalBook. All rights reserved